Veradermics' VDPHL01 meets all primary and secondary endpoints in Phase 3 study

Veradermics announced that its hair-loss candidate VDPHL01 met all primary and secondary endpoints in a Phase 3 study, demonstrating significant hair count gains and a favorable safety profile.

Detected & updated continuously · Source: Nebula